Spanish Breast Cancer Research Group

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Private

Established: 1995-01-01

Employees: 101

Market Cap: -

Website: https://www.geicam.org

Clinical Trials

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab Injectable Solution
Drug: Trastuzumab Injectable Product
Drug: Trastuzumab Injection

First Posted Date: 2013-06-11

Last Posted Date: 2023-04-05

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 166

Registration Number: NCT01875367

Locations: 🇪🇸
Hospital de Mataró, Mataró, Barcelona, Spain
🇪🇸
Hospital de Manacor, Manacor, Illes Balears, Spain
🇪🇸
Hospital General Universitario de Granollers, Granollers, Barcelona, Spain

and more 24 locations

Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer

Completed

Conditions: Metastatic Colorectal Cancer
Metastatic Breast Cancer

First Posted Date: 2012-11-27

Last Posted Date: 2019-12-04

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 143

Registration Number: NCT01733628

Locations: 🇪🇸
Complejo Hospitalario de Jaén, Jaén, Spain
🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain

and more 7 locations

A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer

Terminated

Conditions: Breast Cancer Invasive Nos

First Posted Date: 2012-05-15

Last Posted Date: 2019-01-14

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 26

Registration Number: NCT01598285

Locations: 🇪🇸
Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Nab-paclitaxel

First Posted Date: 2012-03-28

Last Posted Date: 2023-03-30

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 83

Registration Number: NCT01565499

Locations: 🇪🇸
Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain
🇪🇸
Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
🇪🇸
Instituto Oncológico de Guipúzcoa, Donostia-San Sebastián, Guipúzcoa, Spain

and more 10 locations

Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis

Completed

Conditions: Breast Cancer

First Posted Date: 2011-06-21

Last Posted Date: 2023-03-10

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 236

Registration Number: NCT01377363

Locations: 🇪🇸
Hospital General de Elda, Elda, Alicante, Spain
🇪🇸
Hospital de Sagunto, Sagunto, Valencia, Spain
🇪🇸
Hospital Virgen de los Lirios, Alcoy, Alicante, Spain

and more 29 locations

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Dasatinib
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2011-03-02

Last Posted Date: 2023-03-30

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 37

Registration Number: NCT01306942

Locations: 🇪🇸
Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain
🇪🇸
Instituto Catalán de Oncología de Barcelona (Hospital Duran i Reynalds), Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

and more 5 locations

Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Aprepitant

First Posted Date: 2011-02-17

Last Posted Date: 2023-03-07

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 212

Registration Number: NCT01298193

Locations: 🇪🇸
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸
Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
🇪🇸
Hospital del Mar, Barcelona, Spain

and more 10 locations

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Lapatinib
Drug: Trastuzumab

First Posted Date: 2009-02-11

Last Posted Date: 2023-03-31

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 102

Registration Number: NCT00841828

Locations: 🇪🇸
Hospital General de Granollers, Granollers, Barcelona, Spain
🇪🇸
Onkologikoa, Donostia-San Sebastián, Guipuzcoa, Spain
🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain

and more 23 locations

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Drug: Bevacizumab
Drug: Fulvestrant

First Posted Date: 2007-10-17

Last Posted Date: 2023-03-31

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 380

Registration Number: NCT00545077

Locations: 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪
Klinikum Bayreuth, Bayreuth, Germany
🇩🇪
Universitätsklinikum Charité, Berlin, Germany

and more 65 locations

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Anastrozole

First Posted Date: 2007-10-12

Last Posted Date: 2023-03-10

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 870

Registration Number: NCT00543127

Locations: 🇪🇸
Hospital de Sagunto, Sagunto, Valencia, Spain
🇪🇸
Hospital Lluís Alcanyis, Xátiva, Valencia, Spain
🇪🇸
Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain

and more 50 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy